ArticleTurkish journal of medical sciences2025
Clinical characteristics and outcomes in Epstein-Barr virus-positive diffuse large B-cell lymphoma: a multicenter retrospective study.
Article in Turkish journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biological Activity of Stilbenoids Against Fungal, Parasitic, and Viral Pathogens.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: Epstein-Barr virus-positive (EBV+) diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS), is a rare and aggressive subtype of B-cell lymphoma, recognized as a distinct entity in the revised fourth edition of the 2016 World Health Organization (WHO) classification. This retrospective study aims to evaluate the prevalence, clinical and histopathological characteristics, and survival outcomes of patients diagnosed with EBV+ DLBCL-NOS. Materials and methods: This retrospective study included 92 newly diagnosed DLBCL patients treated at two centers between 2016 and 2024. EBV status was determined by in situ hybridization for EBER, with positivity defined as ≥ 50% nuclear staining in tumor cells. Results: Among 92 patients, 81 (88.1%) were EBV-negative and 11 (11.9%) were EBV-positive. The median age was 63 years. EBV-positive patients had significantly more advanced-stage disease (100% versus 71.6%, p = 0.049), higher rates of splenic involvement (72.7% versus 38.3%, p = 0.048), elevated LDH levels (median: 773 U/L versus 326 U/L, p = 0.043), and a higher proportion with high-risk IPI scores (IPI ≥ 4: 63.6% versus 27.2%, p = 0.032). No significant differences were observed in age, sex, bulky disease, extranodal involvement, or molecular subtype. Median PFS was 12 months in the EBV-positive group, whereas it was not reached in the EBV-negative group (p = 0.005). EBV positivity was identified as an independent risk factor for inferior PFS (HR: 6.256, 95% CI: 2.398-16.324, p < 0.001), but not for overall survival (OS). Patients with ECOG performance status ≥ 2 and bone marrow involvement also had significantly worse PFS and OS. Conclusion: EBV+ DLBCL is characterized by distinct clinical features, including advanced-stage disease and poorer PFS. Variability in reported prevalence highlights the need for standardized diagnostic criteria. Further research is essential to develop tailored therapeutic strategies and improve outcomes for this rare lymphoma subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.